fda perspective---qbd considerations for analytical methods
DESCRIPTION
FDA considerations, QbDTRANSCRIPT
![Page 1: FDA Perspective---QbD Considerations for Analytical Methods](https://reader035.vdocuments.us/reader035/viewer/2022081809/55cf94f0550346f57ba57305/html5/thumbnails/1.jpg)
QbD Considerations for Analytical Methods -
FDA
Perspective
IFPAC Annual MeetingBaltimore, January 25, 2013
Sharmista Chatterjee, Ph.D.CMC Lead for QbD ONDQA/CDER/FDA
![Page 2: FDA Perspective---QbD Considerations for Analytical Methods](https://reader035.vdocuments.us/reader035/viewer/2022081809/55cf94f0550346f57ba57305/html5/thumbnails/2.jpg)
2
Outline•
Role of analytics in drug development
•
QbD approach for analytical method development–
Current status
–
Regulatory considerations•
Ongoing collaborative research
•
Concluding remarks
![Page 3: FDA Perspective---QbD Considerations for Analytical Methods](https://reader035.vdocuments.us/reader035/viewer/2022081809/55cf94f0550346f57ba57305/html5/thumbnails/3.jpg)
3
Analytical Methods –
A Key Part of Control Strategy
•
Control Strategy (ICH Q10)–
assures process performance and product quality
–
includes parameters and attributes related to drug substance and drug product materials
–
includes components, facility and equipment operating conditions
–
includes in-process controls, finished product specification, and the associated methods and frequency of monitoring and control
Right Analytics at the Right Time
![Page 4: FDA Perspective---QbD Considerations for Analytical Methods](https://reader035.vdocuments.us/reader035/viewer/2022081809/55cf94f0550346f57ba57305/html5/thumbnails/4.jpg)
4
Role of Analytics in Drug Development
Process Monitoring & ControlMake corrections before failures occurs
Allows implementation of RTRT
Continuous Process VerificationMonitor trends in product quality
Key Role Throughout
Drug Product Life
Cycle
Drug Substance SynthesisScreening tool to select optimal chemistriesMonitor crystal growthDrug Product ManufactureUnderstand excipient-active interactionsMeasure CQA during experimentation
Pharmaceutical Development
![Page 5: FDA Perspective---QbD Considerations for Analytical Methods](https://reader035.vdocuments.us/reader035/viewer/2022081809/55cf94f0550346f57ba57305/html5/thumbnails/5.jpg)
5
Variations in an Analytical Method
MethodParameters
InstrumentSettings
CalibrationModel
SampleCharacteristics
Analytical Results
Many Factors can affect analytical results.
e.g. variations in instrument, sample, method, choice of model
![Page 6: FDA Perspective---QbD Considerations for Analytical Methods](https://reader035.vdocuments.us/reader035/viewer/2022081809/55cf94f0550346f57ba57305/html5/thumbnails/6.jpg)
6
Benefits of Application of QbD Approach to Analytical Methods
•
Development of a robust method•
Understand, reduce and control sources of variability
•
Applicable throughout the life cycle of the method•
Regulatory flexibility
−
Movements within “Analytical Design Space”
are not considered a change in method
![Page 7: FDA Perspective---QbD Considerations for Analytical Methods](https://reader035.vdocuments.us/reader035/viewer/2022081809/55cf94f0550346f57ba57305/html5/thumbnails/7.jpg)
7
ICH Q8(R2) and Analytical Methods
•
ICHQ8(R2) doesn’t explicitly discuss analytical method development.
•
However, concepts apply:−Application of Science and Risk based
methodology −Systematic approach that includes: risk
assessment, defining a design space, control strategy and continual improvement to increases method robustness and understanding
![Page 8: FDA Perspective---QbD Considerations for Analytical Methods](https://reader035.vdocuments.us/reader035/viewer/2022081809/55cf94f0550346f57ba57305/html5/thumbnails/8.jpg)
8
Determine what to measure and where/when to measure it. Develop
measurement requirements based on product QTPP and CQA.
Select appropriate analytical technique for desired measurement.
Define method performance criteria.
Assess risks of method operating parameters and sample variation. Can use risk assessment tools (e.g. FMEA)
Examine potential multivariate interactions (DoE and design space). Understand method robustness and ruggedness
Define control space and system suitability, meet method performance criteria
Monitor method performance; update as needed as process and analytical technology evolves
Target Measurement
Select Technique
Risk assessment
Method Develop/ Val
Control strategy
Continual Improvement
QbD Approach for Analytical Methods
![Page 9: FDA Perspective---QbD Considerations for Analytical Methods](https://reader035.vdocuments.us/reader035/viewer/2022081809/55cf94f0550346f57ba57305/html5/thumbnails/9.jpg)
9
Example of QbD Approach
Select Suitable Analytical Method
Identify “ATP”(Analytical Target Profile)e.g. in terms of accuracy,
precision
ATP
Risk Assessment
Design Space for Analytical
MethodAnalytical Method Implementation
Cont
inuo
us
Impr
ovem
ent
Factors AffectingMethod Performance
e.g. Column type, temperature, pH etcfor HPLC
![Page 10: FDA Perspective---QbD Considerations for Analytical Methods](https://reader035.vdocuments.us/reader035/viewer/2022081809/55cf94f0550346f57ba57305/html5/thumbnails/10.jpg)
10
Current Status
•
FDA has approved some NDA applications applying QbD approach to analytical methods (e.g. HPLC and UV)
•
Regulatory flexibility has been granted for movements within the defined analytical method design space/ “MODR”
(Method
Operable Design Region)
![Page 11: FDA Perspective---QbD Considerations for Analytical Methods](https://reader035.vdocuments.us/reader035/viewer/2022081809/55cf94f0550346f57ba57305/html5/thumbnails/11.jpg)
11
Parallel's with Drug Product Development
Product QbD (Q8(R2)) Analytical QbD (example terminology)
QTPP ATP (Analytical Target Profile)
Design Space MODR (Method Operable Design Region)
![Page 12: FDA Perspective---QbD Considerations for Analytical Methods](https://reader035.vdocuments.us/reader035/viewer/2022081809/55cf94f0550346f57ba57305/html5/thumbnails/12.jpg)
12
Analytical Target Profile (ATP)What is ATP? • Prospective summary of measurement requirements thatensure that the method is ‘fit for purpose’
• Not linked to any particular method• More than one technique can satisfy a single ATP
Regulatory Considerations for Implementing ATP• Not all methods with same ATP are inter-changeable without prior regulatory communication
- E.g. from HPLC to NIR
• Can use comparability protocols
![Page 13: FDA Perspective---QbD Considerations for Analytical Methods](https://reader035.vdocuments.us/reader035/viewer/2022081809/55cf94f0550346f57ba57305/html5/thumbnails/13.jpg)
13
Analytical Method “Design Space”/ “MODR”
•
A science and risk based and multivariate approach to evaluate effects of various method input variables on method performance
•
Typically DoE
(Design of Experiment) is used to find ranges for instrument operating parameters, to understand sample preparation variations and variations of method precision.
•
Method performance criteria are response factors •
Can be conducted together with method validation
![Page 14: FDA Perspective---QbD Considerations for Analytical Methods](https://reader035.vdocuments.us/reader035/viewer/2022081809/55cf94f0550346f57ba57305/html5/thumbnails/14.jpg)
14
Considerations for Implementing MODR
•
Availability of adequate data to support proposed design space/MODR–
Includes variation in raw materials, sites, analysts
–
Appropriately chosen experimental protocol–
Statistical confidence shown throughout the MODR
•
Assess validation requirements identified in ICH Q2(R1) (e.g. specificity, accuracy, precision, robustness, linearity, LOQ/LOD) across MODR
•
Confirm system suitability throughout MODR
![Page 15: FDA Perspective---QbD Considerations for Analytical Methods](https://reader035.vdocuments.us/reader035/viewer/2022081809/55cf94f0550346f57ba57305/html5/thumbnails/15.jpg)
15
Laboratory Considerations for Verification of MODR
•
Determine that the method meets the acceptance criteria across the MODR–
Begin with the applicant’s model
–
Appropriate selection of experiments to evaluate MODR•
Comparison with applicants results
•
Part of FDA's Laboratory Methods Validation Program
![Page 16: FDA Perspective---QbD Considerations for Analytical Methods](https://reader035.vdocuments.us/reader035/viewer/2022081809/55cf94f0550346f57ba57305/html5/thumbnails/16.jpg)
16
FDA-EMA Collaborative Research on QbD for Analytical Methods
•
Joint research with FDA’s laboratory/review divisions and EMA–
Initiated in January, 2013
•
Goal of this project is to:–
Develop analytical methods (e.g. HPLC) based on QbD paradigm
–
Define protocols for method transfer –
Establish methodology for validation of MODR upon site transfer
–
Define review criteria for evaluation of QbD based analytical methods
![Page 17: FDA Perspective---QbD Considerations for Analytical Methods](https://reader035.vdocuments.us/reader035/viewer/2022081809/55cf94f0550346f57ba57305/html5/thumbnails/17.jpg)
17
FDA-EMA Harmonization
•
Areas of harmonization so far–
Considerations for defining and implementing ATP
–
Data requirements to support a MODR
•
Elements that warrant harmonization–
Level of detail in regulatory filings regarding MODR
–
Methods for regulatory communication of verification and maintenance of MODR
![Page 18: FDA Perspective---QbD Considerations for Analytical Methods](https://reader035.vdocuments.us/reader035/viewer/2022081809/55cf94f0550346f57ba57305/html5/thumbnails/18.jpg)
18
Concluding Remarks
•
Analytics play a key role in the implementation of QbD
•
QbD can offer more flexibility for analytical methods, but requires–
High degree of process, product and analytical method understanding
–
Robust quality systems•
Applicants are encouraged to discuss novel QbD implementation approaches with FDA prior to submission
![Page 19: FDA Perspective---QbD Considerations for Analytical Methods](https://reader035.vdocuments.us/reader035/viewer/2022081809/55cf94f0550346f57ba57305/html5/thumbnails/19.jpg)
19
AcknowledgmentsChristine Moore, ONDQA, FDACindy Buhse, DPA, OTR, FDAJohn Kauffman, DPA, OTR, FDAYubing
Tang, ONDQA, FDA
Robert Lu, ONDQA, FDA